Clinical trial of stem cell therapy for stroke begun
SanBio Inc. today announced that the first 6 patients, of a total of 18, have been successfully administered SB623, a new allogeneic stem cell therapy product, in the first clinical trial testing the safety and efficacy of the therapy in patients suffering from chronic deficits resulting from stroke. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been reported. SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke. "This represents a major milestone in the human clinical testing of this important new approach for regenerative medicine," said Keita Mori, SanBio CEO. "We are pleased to learn that the initial dose level was well tolerated."